Potential indications for deep brain stimulation in neurological disorders: an evolving field

Abstract

Deep brain stimulation (DBS) is an established therapy for appropriately selected patients with movement disorders and neuropsychiatric conditions. Although the exact mechanisms and biology of DBS are not fully understood, it is a safe and well-tolerated therapy for many refractory cases of neuropsychiatric disease. Increasingly, DBS has been explored in other conditions with encouraging results. In this paper, available data is reviewed and new DBS targets, challenges and future directions in neurological disorders are explored. A detailed search of the medical literature discussing the potential use of DBS for neurological disorders excluding accepted indications was conducted. All reports were analyzed individually for content and redundant articles were excluded by examining individual abstracts. The level of evidence for each indication was summarized. Multiple studies report promising preliminary data regarding the safety and efficacy of DBS for a variety of neurological indications including chronic pain, tinnitus, epilepsy, Tourette syndrome, Huntington's disease, tardive dyskinesia and Alzheimer's disease. The initial results of DBS studies for diverse neurological disorders are encouraging but larger, controlled, prospective, homogeneous clinical trials are necessary to establish long-term safety and effectiveness. The field of neuromodulation continues to evolve and advances in DBS technology, stereotactic techniques, neuroimaging and DBS programming capabilities are shaping the present and future of DBS research and use in practice.

The Future of GDNF in Parkinson's Disease

“…Neurosurgical experience and advances would support lowering intervention thresholds. Safety data from a wealth of procedures with an indwelling lead/cannula-such as deep brain stimulation (DBS) where a number of anatomical locations, including deep structures, have been targeted-support the lower thresholds as a relatively low rate of serious adverse events are now reported (Budman et al, 2018). In line with DBS safety, striatal intraparenchymal fetal mesencephalic transplantation has demonstrated that the neurosurgical procedure itself is very safe (Lindvall, 2015).…”

Proceedings of the Seventh Annual Deep Brain Stimulation Think Tank: Advances in Neurophysiology, Adaptive DBS, Virtual Reality, Neuroethics and Technology

“…At present, 28 cerebral targets are utilized in DBS according to this registry. These targets (inclusive of multiple sites being used to treat the same disorder) included: PD [nucleus basalis of Meynert, STN, GPi, ventral intermediate thalamic nucleus, pedunculopontine nucleus (PPN)], depression (subgenual cingulate gyrus, habenula, medial forebrain bundle, inferior thalamic peduncle, ventral capsule/ventral striatum, nucleus accumbens and anterior limb of the internal capsule;), and obsessive-compulsive disorder (medial thalamus, inferior thalamic peduncle, ventral capsule/ventral striatum, nucleus accumbens, anterior limb of the internal capsule, bed nucleus of the stria terminalis and the STN; Budman et al, 2018;Lee et al, 2019). Nearby targets for the same disorder often may be no more than a few millimeters apart.…”

Fostering the trustworthiness of researchers: SPECS and the role of ethical reflexivity in novel neurotechnology research

“…The positive value of novel neurotechnologies lies in their potential to improve dramatically the life prospects of many people. These include life-changing therapies for conditions like Parkinson’s disease, essential tremor, stroke, paralysis, Alzheimer’s disease and treatment-resistant depression (Budman et al, 2018; Lozano and Lipsman, 2013). People with paralysis or limb loss could use brain-controlled prosthetics to transcend their bodily limitations (Wood, 2017).…”